A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer

LESSONS LEARNED. The combination of everolimus and low‐dose prednisone administered daily was hypothesized to prevent noninfectious pneumonitis (NIP) and mucositis, two common adverse events related to everolimus. Although mucositis was detected in only one case, all‐grade NIP occurred in four of ei...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Lolli, Cristian, Gallà, Valentina, Schepisi, Giuseppe, Barone, Domenico, Burgio, Salvatore Luca, Maugeri, Antonio, Vertogen, Bernadette, Amadori, Dino, De Giorgi, Ugo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2017
Konular:
Clinical Trial Results
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507652/
https://ncbi.nlm.nih.gov/pubmed/28546463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0154
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller